In clinical samples, JMJD6 and EZH2 expression significantly correlated in both normal and tumor samples, however the strongest correlation was observed in triple-negative breast cancer (TNBC) subtype. The gene discussed is EZH2; the disease is triple-negative breast carcinoma.